West Pharmaceutical Services, Inc.

“West Pharmaceutical Services is a structurally exceptional business — regulatory co-qualification lock-in, HVP mix-shift, and biologics/GLP-1 tailwinds create a near-irreplaceable position in injectable drug containment with durable above-average returns on capital. The moat is wide, widening, and well-understood. The defect is entirely in the price: at ~31x EV/EBITDA and 36x forward earnings near a 52-week high, the market fully discounts a decade of strong execution. Probability-weighted intrinsic value (~$21B) sits below today's $24.4B market cap, offering no margin of safety, and expected 10-year returns of 1.5–3x are insufficient compensation for the uncertainty of the hold. This is a business to own at the right price — and today is not that price.”